Intervet Inc.

Akzo N.v.

Intervet International B.v.

Theodorus Jansen

Maarten Hendrik Witvliet

Nicolaas Visser

Huchappa Gowda Jayappa

Theodorus Petrus Maria Schetters

Henricus Johannes Maria Jagt

Lammert Cornelius

Guntram Paul

Virgil Elisabeth Joseph Caspar Schijns

Erwin Mombarg

Erik Hermkens

Theodorus Petrus Schetters

Engelbertus J Janssen

Marco Groot

Virgil Elisabeth Schijns

Daniel GE Goovaerts

The present invention is based on the discovery of new and advantageous properties of a class of known polymeric emulsifiers. The emulsifier class was found to be resistant to degradation by crude bacterial antigen preparations, which degradation caused emulsion instability when using prior art emulsifiers. This allows the formulation of safe, stable, and effective vaccines based on these emulsions of oil and water comprising such bacterial antigens. The polymeric emulsifier is a block copolymer having a general formula A-B-A in which component B is the divalent residue of a water-soluble polyalkylene glycol and component A is the residue of an oil-soluble complex monocarboxylic acid. Preferred emulsifier is a PEG-30-di-(polyhydroxystearate).

Stable emulsions of bacterial antigens

The present invention relates to a combination vaccine for swine, comprising non-replicating antigen from porcine circovirus type 2 (PCV2), and live porcine reproductive and respiratory syndrome virus (PRRSV); the combination vaccine is formulated as an oil-in-water emulsion, and is adjuvated with squalane and vitamin E-acetate. This combination vaccine was found to be immunologically effective against all pathogens: PCV2, and PRRSV.

Combination vaccine for swine

The present invention describes a process for the preparation of an antigen composition, which antigen composition can be used to prepare a ready-to-use vaccine for swine, for preventing or reducing infection byor PCV2 and associated signs of disease. The process is characterised in that it comprises a step of admixing a PCV2 antigen to a pre-formed antigen/adjuvant complex of anantigen adsorbed to an Aluminium-hydroxide adjuvant. This way a PCV2/combination vaccine can be prepared that is highly effective already after a single administration, against infection and disease byand PCV2 either when in single or in combined infections. Also the vaccine has very good safety upon administration, is ready-to-use, and is economically feasible.

Process for ready-to-use PCV/M.Hyo combination vaccine

The present invention generally relates to the fields of parasitology and immunology, and especially to a vaccine againstticks. In particular the invention relates to a composition comprising a first and a second protein, in particular Bm86 and Subolesin proteins, including their homologs or immunogenic fragments; to the use of such a composition as a vaccine againstticks, and to the use of the first and the second isolated proteins for the vaccination of a target againstticks.

Vaccine against Rhipicephalus ticks

The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.

Emulsion containing a non-live medicinal substance

The present invention pertains to a method for keeping an immunogenic composition available for administration to an animal, wherein said composition comprises an antigen and an emulsion which is a single emulsion at a first temperature below a body temperature of the animal and which emulsion reverses at a second temperature between the first temperature and the body temperature, said method comprising providing the composition, freezing the composition, and storing the frozen composition until it is needed for administration to the animal. The invention also pertains to a method for testing an immunogenic composition, and an immunogenic composition, optionally in combination with specific instructions for storing the composition.

Method for keeping an immunogenic composition available for administration to an animal

Personal care or cosmetic oil in water emulsions include an oil emulsifier and a combination of a Xanthan polysaccharide and a polyglucomannan polysaccharide to provide enhanced stability even at low emulsifier stabilizer levels. The emulsifier stabilizer system provides stable emulsions without dominating system rheology, particularly viscosity. Thus, the emulsions can have a low viscosity suitable for formulation as milks or thin lotions, or can be thickened, desirably by thickening agents other than the Xanthans and/or polyglucomannan, to provide emulsion creams or gels. This enables the system to be used very flexibly in end use applications. The emulsifier is desirably a non-ionic emulsifier and particularly is a combination of a low HLB and a high HLB emulsifier and can be formulated with conventional alcohol ethoxylate surfactants or from non-EO surfactants e.g. sucrose ester high HLB surfactants and citrate or sorbitan ester low HLB surfactants.

Injectable water-in-oil emulsions

According to the present invention antibody preparations are more stable during storage if in addition they contain a mixture of at least one polyoxypropylene-polyoxyethylene block polymer (such as Pluronic F68) and at least one phospholipid (such as lecithin).

Growing community of inventors

Venray, Netherlands

Theodorus Jansen